Genzyme Corp (Cambridge, MA), which has been trying to resolve its manufacturing problems at its Allston Landing plant last June, has signed a new supply agreement with Hospira Inc (Lake Forest, Illinois) for fill-finish operations of seven products, according to a recent report by Reuters.
In May, Genzyme agreed to terms of a consent decree with the FDA, which requires the company to move its fill-finish operations out of the Allston Landing plant for Cerezyme, Fabrazyme, and Thyrogen, and Myozyme. Under the new agreement, Hospira will now also handle the fill-finish operations for Lumizyme, Thymoglobulin, Campath, and other products now being developed by Genzyme.
Under the terms of the consent decree Genzyme also will pay the government $175 million in profits from past sales of certain drugs.
Genzyme Expects $175 Million Fine
Genzyme to Exit Fill-Finish Operations at Allston Landing Plant
FDA Takes Enforcement Action Regarding Genzyme's Allston Plant